| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Folate receptor (FR) is the primary molecular target. The dye is conjugated to folic acid to target FR, which is overexpressed in many cancer cells.
|
|---|---|
| ln Vitro |
S0456 is a near-infrared (NIR) fluorescent dye with an excitation (Ex) of 788 nm and emission (Em) of 800 nm. S0456 binds to the folate receptor (FR). It is a raw material that plays a crucial role in the construction of the folate receptor-targeted near-infrared dye OTL 38.
|
| ln Vivo |
There is no specific in vivo activity data available for this compound beyond its use as a component of a tumor-targeting imaging agent. As part of OTL38, it is used to visualize folate receptor-positive tumors in vivo.
|
| Enzyme Assay |
A standard protocol involves measuring the absorbance and fluorescence spectra of S0456 in a suitable solvent (e.g., PBS) using a spectrophotometer. The excitation and emission peaks should be confirmed at 788 nm and 800 nm, respectively. There is no enzyme/receptor binding assay for the dye itself.
|
| Cell Assay |
There is no specific cellular experiment protocol for S0456 alone, as it is a raw material. A general protocol for its conjugate involves incubating FR-positive cancer cells with S0456-folate conjugate (e.g., 1-10 uM) for 1-2 hours at 37degC. After washing, cells are imaged using a NIR fluorescence microscope.
|
| Animal Protocol |
A typical in vivo protocol involves intravenous injection of S0456-folate conjugate into a mouse xenograft model bearing FR-positive tumors. After a suitable circulation time (e.g., 1-24 hours), the animal is placed under an in vivo imaging system to visualize tumor-specific fluorescence.
|
| ADME/Pharmacokinetics |
General PK properties for S0456 alone are not applicable, as it is a raw material. The PK properties of its conjugate (OTL38) are known: it has a terminal half-life of approximately 5 hours in humans and is eliminated primarily through the kidneys.
|
| Toxicity/Toxicokinetics |
General toxicity for NIR dyes is considered low. S0456 itself is a raw material and is not used in vivo. Its conjugate, Pafolacianine (OTL38), has been evaluated in clinical trials and approved for use, showing a manageable safety profile with mild to moderate adverse effects.
|
| References | |
| Additional Infomation |
S0456 is a research tool for developing FR-targeted NIR imaging agents. Pafolacianine (OTL38), derived from S0456, is an FDA-approved imaging agent for intraoperative detection of folate receptor-positive ovarian and lung cancer lesions. This product is for research use only.
|
| Molecular Formula |
C38H47N2O12S4CL.NA
|
|---|---|
| Molecular Weight |
910.489
|
| Exact Mass |
952.115
|
| CAS # |
1252007-83-2
|
| PubChem CID |
16088101
|
| Appearance |
Green to dark green solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
60
|
| Complexity |
1940
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[NaH].C(N1C(C(C)(C)C2=CC(S(O)(=O)=O)=CC=C12)=CC=C1CCCC(C=CC2C(C3=CC(S([O-])(=O)=O)=CC=C3[N+]=2CCCCS(O)(=O)=O)(C)C)=C1Cl)CCCS(O)(=O)=O
|
| InChi Key |
RNYJFPBIWHZDBN-UHFFFAOYSA-K
|
| InChi Code |
InChI=1S/C38H47ClN2O12S4.3Na/c1-37(2)30-24-28(56(48,49)50)14-16-32(30)40(20-5-7-22-54(42,43)44)34(37)18-12-26-10-9-11-27(36(26)39)13-19-35-38(3,4)31-25-29(57(51,52)53)15-17-33(31)41(35)21-6-8-23-55(45,46)47;;;/h12-19,24-25H,5-11,20-23H2,1-4H3,(H3-,42,43,44,45,46,47,48,49,50,51,52,53);;;/q;3*+1/p-3
|
| Chemical Name |
trisodium;(2E)-2-[(2E)-2-[2-chloro-3-[(E)-2-[3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indol-1-ium-2-yl]ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-3,3-dimethyl-1-(4-sulfonatobutyl)indole-5-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0983 mL | 5.4915 mL | 10.9831 mL | |
| 5 mM | 0.2197 mL | 1.0983 mL | 2.1966 mL | |
| 10 mM | 0.1098 mL | 0.5492 mL | 1.0983 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
